Individual applications of clopidogrel after coronary artery bypass grafting

Individualized antiplatelet therapy after coronary artery bypass grafting

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007646

Enrollment

Unknown

Registered

2015-12-22

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

Experimental group:oral administration of clopidogrel according to CYP2C19 genotype

Control group:oral administration of clopidogrel 75mg/d

Eligibility

Sex/Gender

Male

Age

45 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. aged <70 years; 2. patients who were diagnosed as coronary heart disease by coronary angiography undergoing isolated coronary artery bypass grafting surgery; 3. without a contraindications of clopidogrel; 4. patients signing informed consent.

Exclusion criteria

Exclusion criteria: 1. long-term oral proton pump inhibitor; 2. platelets count <100*10^9/L, neutrophils count <1.8*10^9/L; 3. risk of serious bleedin; 4. preoperative concomitant of malignant tumor.

Design outcomes

Primary

Measure	Time frame
Platelet aggregation;incidence of bleeding;Major adverse cardiac events;rate of rehospitalization;	—

Contacts

Public ContactJi Qiang

drjiqiang@tongji.edu.cn+86 15921230800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026